<unk>  inhibits cellular signalling by targeting multiple receptor tyrosine kinases (RTKs). These include all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), which play a role in both tumor angiogenesis and tumor cell proliferation. The simultaneous inhibition of these targets therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage.<unk>  also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors. It has been recommended as a second-line therapy for patients whose tumors develop mutations in c-KIT that make them resistant to imatinib, or who the cannot tolerate the drug. In addition,<unk>  binds other receptors. These include: * RET * CD114 * CD135 The fact that<unk>  targets many different receptors, leads to many of its side effects<unk> ch as the classic hand-foot syndrome, stomatitis, and other dermatologic toxicities.
Sunitinib
Ceritinib
Axitinib
Gilteritinib
Abrocitinib
Erdafitinib
Oclacitinib
Upadacitinib